BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38030173)

  • 1. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
    Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R
    Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
    Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
    Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
    Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
    Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
    Shafi S; Aung TN; Xirou V; Gavrielatou N; Vathiotis IA; Fernandez A; Moutafi M; Yaghoobi V; Herbst RS; Liu LN; Langermann S; Rimm DL
    Lab Invest; 2022 Oct; 102(10):1143-1149. PubMed ID: 35581307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11.
    Idel C; Fleckner J; Plötze-Martin K; Werner L; Rades D; Theodoraki MN; Hofmann L; Huber D; Leichtle A; Hoffmann TK; Bruchhage KL; Pries R
    BMC Cancer; 2024 Apr; 24(1):459. PubMed ID: 38609887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma.
    Netzer C; von Arps-Aubert V; Mačinković I; von der Grün J; Küffer S; Ströbel P; von Knethen A; Weigert A; Beutner D
    Front Immunol; 2023; 14():1240394. PubMed ID: 38322012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
    Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
    Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.